Abner O Rayapati
Overview
Explore the profile of Abner O Rayapati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lile J, Shellenberg T, Babalonis S, Hatton K, Hays L, Rayapati A, et al.
Psychopharmacology (Berl)
. 2024 Feb;
241(6):1227-1236.
PMID: 38383903
Rationale: Understanding mechanisms of drug use decisions will inform the development of treatments for opioid use disorder (OUD). Decision-making experiments using neurobehavioral approaches require many trials or events of interest...
2.
Meadows A, Strickland J, Hyder S, Basconi R, Stull M, Wagner F, et al.
Int J Psychiatry Med
. 2023 Aug;
59(2):218-231.
PMID: 37594029
Objective: Early adversity, such as adverse childhood experiences (ACEs), is a risk factor for the development of substance use disorder (SUD). ACEs are associated with earlier initiation of substance use....
3.
Strickland J, Hatton K, Hays L, Rayapati A, Lile J, Rush C, et al.
Behav Pharmacol
. 2023 Jul;
34(5):275-286.
PMID: 37403694
Commodity purchase tasks provide a useful method for evaluating behavioral economic demand in the human laboratory. Recent research has shown how responding to purchase tasks for blinded drug administration can...
4.
Regnier S, Stoops W, Lile J, Alcorn 3rd J, Bolin B, Reynolds A, et al.
Pharmacol Biochem Behav
. 2023 Feb;
224:173526.
PMID: 36805862
The FDA has not yet approved a pharmacotherapy for cocaine use disorder despite nearly four decades of research. This study determined the initial efficacy, safety, and tolerability of naltrexone-bupropion combinations...
5.
Stoops W, Strickland J, Hatton K, Hays L, Rayapati A, Lile J, et al.
Pharmacol Biochem Behav
. 2022 Sep;
220:173466.
PMID: 36152876
Preclinical research has sought to understand the role of the orexin system in cocaine addiction given the connection between orexin producing cells in the lateral hypothalamus and brain limbic areas....
6.
Rush C, Stoops W, Lile J, Alcorn 3rd J, Bolin B, Reynolds A, et al.
Drug Alcohol Depend
. 2020 Dec;
218:108413.
PMID: 33290875
Rationale: Cocaine use disorder is an unrelenting public health concern. Despite nearly four decades of research, an FDA approved medication is not yet available. Objectives: The objective of this human...
7.
Stoops W, Strickland J, Hays L, Rayapati A, Lile J, Rush C
Pharmacol Biochem Behav
. 2020 Sep;
198:173037.
PMID: 32891709
Rationale: Glutamate systems play an important role in the abuse related effects of alcohol. n-Acetylcysteine, a drug that promotes glutamate homeostasis, attenuates a range of alcohol effects in preclinical models....
8.
Tindell W, Su A, Oros S, Rayapati A, Rakesh G
Psychosomatics
. 2020 Aug;
61(6):735-738.
PMID: 32763020
No abstract available.
9.
Bahrani A, Kong W, Shang Y, Huang C, Smith C, Powell D, et al.
J Biophotonics
. 2020 Jun;
13(10):e202000073.
PMID: 32533642
Diagnosis of cerebrovascular disease (CVD) at early stages is essential for preventing sequential complications. CVD is often associated with abnormal cerebral microvasculature, which may impact cerebral-autoregulation (CA). A novel hybrid...
10.
Hobbs M, Wolters W, Rayapati A
J Psychiatr Pract
. 2020 Jan;
26(1):58-62.
PMID: 31913971
Bosch-Boonstra-Schaaf optic atrophy syndrome (BBSOAS) is a recently described autosomal dominant disorder caused by mutations in the nuclear receptor subfamily 2 group F member 1 (NR2F1) gene. Its common features...